Sector consensus Takeda Pharmaceutical Company Limited

Equities

Delayed Japan Exchange Other stock markets 01:30:00 2025-12-15 EST			5-day change	1st Jan Change
4,481.00 ^JPY	+0.74%		+1.61%	+7.18%

12-07	Takeda, Protagonist Report One-Year Rusfertide Gains in PV trial	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
TAKEDA PHARMACEUTICAL COMPANY LIMITED	JP¥4,946.14	+11.2%	14
ELI LILLY AND COMPANY	US$1,075.74	+4.69%	27
JOHNSON & JOHNSON	US$206.34	-2.48%	24
ABBVIE INC.	US$244.82	+9.63%	28
ROCHE HOLDING AG	CHF 323.28	+2.05%	18
ASTRAZENECA PLC	GBX 201.26	+12.08%	19
NOVARTIS AG	CHF 135.31	+2.06%	19
MERCK & CO., INC.	US$107.46	+7.14%	26
NOVO NORDISK A/S	DKK 393.29	+22.46%	20
AMGEN INC.	US$325.88	+2.56%	27
GILEAD SCIENCES, INC.	US$131.8	+9.47%	26
PFIZER INC.	US$28.91	+11.86%	24
SANOFI	€105.2	+26.26%	21
VERTEX PHARMACEUTICALS INCORPORATED	US$489.48	+8.28%	25
BRISTOL-MYERS SQUIBB COMPANY	US$53.41	+1.91%	22
GSK PLC	GBX 18.64	+2.14%	18
CHUGAI PHARMACEUTICAL CO., LTD.	JP¥8,571.43	+0.33%	14
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	CN¥81.04	+28.06%	18
ALNYLAM PHARMACEUTICALS, INC.	US$492.71	+23.94%	24
Average	943.8	+9.67%	22
Weighted average by Cap.	622.18	+6.89%	23